"Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs

Key Points Semaglutide (Ozempic, Wegovy) reduces hunger but doesn't completely eliminate it feeling some hunger is normal Full appetite-suppressing effects take 4-5 weeks to develop as the medication reaches steady-state levels Diet quality, sleep, stress, and emotional eating significantly impact hunger even while on semaglutide Solutions include eating protein-rich meals, managing stress, improving sleep, and staying physically active You started Ozempic or Wegovy after hearing success stories from friends or reading promising headlines
Median duration of treatment was similar for the three groups (Ozempic: 43 weeks
How to Prevent Ozempic Overdose Maintaining healthy blood sugar levels is crucial for staying healthy
You can switch between the two treatments after a seven day break between your final Mounjaro dose and your first Wegovy dose
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION)